RU2232993C1 - Method for assay of functional activity of human complement factor b - Google Patents

Abstract

FIELD: medicinal immunology.

SUBSTANCE: invention relates to methods for assay of functional activity of complement factors in human serum blood and can be used in diagnosis of some diseases and in biological preparations. Method involves sorption of activator of the complement alternative pathway into microplate wells and then solution containing reagent RB and analyzed sample containing human complement factor B with unknown activity are added. Incubation is carried out in the presence of Mg²⁺ ions and in the absence of Ca²⁺ ions and conjugate of enzyme with antibodies raised against the human component C3 and substrate for this enzyme are added. The calculation of factor B activity is carried out by the amount of formed product of enzymatic reaction. Invention provides the development of method allowing the assay of functional activity of factor B of alternative pathway of the human complement system.

EFFECT: improved assay method.

1 tbl, 4 ex

Description

The invention relates to medical immunology, and in particular to methods for determining the functional activity of complement factors in human serum in the diagnosis of a number of diseases and in biological preparations.

The most promising of modern methods for determining serum proteins is enzyme immunoassay due to its sensitivity, selectivity and the ability to automate the analytical process. However, the methods available today for enzyme immunoassay of complement proteins allow only their content to be determined as antigen. Nevertheless, the most informative is the assessment of the functional activity of these proteins, which characterizes the development of the pathological process. As for the determination of the functional activity of complement factor B, the hemolytic method [1] for determining the activity of B, which manifests itself in the activation of the system along an alternative path, is not very reproducible and is reluctantly used by clinicians because of the difficulties associated with the preparation of the hemolytic system for erythrocyte-based rabbit.

The objective of the claimed invention is to develop a method that allows to determine the functional activity of the factor In an alternative way of the human complement system based on the enzyme immunoassay.

The task is achieved by developing a determination method that provides for sorption in the wells of a microplate of an activator of an alternative complement pathway selected from the series: immunoglobulin A, immunoglobulin G, component C3, lipopolysaccharide, then introducing a solution containing RB reagent (human serum devoid of activity of factor B), and an analyzed sample containing factor B of a human complement with unknown activity, incubation in the presence of Mg ^{2+ ions} and in the absence of ion in Ca ²⁺ (during which the formation of C3 convertase (C3bBb) takes place on the sorbed activator of the alternative pathway in amounts depending on the concentration of the functionally active determined factor B, as well as the activation of component C3 by this convertase and covalent binding of the latter on the sorbed activator. Thus , the amount of bound C3 depends on the amount of C3 convertase, i.e., the amount of determined factor B. The amount of component C3 covalently bound as a result of activation is determined by the product of the farm -commutative reaction by antibodies to C3 fraction of immunoglobulins G, conjugated with enzyme. Thus, the determination of the functional activity of factor B is achieved by an enzyme immunoassay suitable for standardization.

The technical result of the claimed invention is the development of a simplified method for determining the functional activity of factor B of a human complement, with good reproducibility of the results and the absence of the need to use such poorly stored and difficult to standardize components, such as red blood cells.

Example 1. Determination of the functional activity of the preparation of factor B. Dissolve the activator of the alternative complement pathway - immunochemically pure IgA in 0.05 M sodium carbonate buffer, pH 9.5, at concentrations of 10-100 μg / ml and add 100 μl of solution to each well flat-bottomed polystyrene 96-well plate. Close the lid and leave overnight at 4 ° C. The tablet is washed three times with Veronal buffer solution, pH 7.4, containing 0.15 M NaCl, 10 mM ethylene glycol bis (β-aminoethyl ether) -N, N, N ', N'-tetraacetic acid and 5 mM MgCl ₂ ( Mg-EGTA), pouring 150 μl into each well, then the plate is dried by shaking out the remaining liquid. 100 μl of a Mg-EGTA solution containing 10 μl of RB reagent (RB is human serum devoid of factor B while maintaining the activities of other components and complement factors, obtained, for example, by heating it for 30 minutes at 50 ° C, is added to the wells of a row tablet). ) and an assayed sample containing factor B with unknown activity. After incubation in a thermostat for 1 h at 37 ° C, twice washing with phosphate buffer, pH 7.4, containing 0.15 M NaCl and 0.05% tween-20, and draining the plate, 100 μl of peroxidase conjugate are added to each well with antibodies against component C3 person in the same buffer in a selected dilution. After incubating in a thermostat for 1 h at 37 ° C, washing twice with detergent, and draining the plate, 100 μl of substrate buffer (10 mg of orthophenylenediamine in 25 ml of citrate-phosphate buffer, pH 5.0, and 50 μl 3 % hydrogen peroxide). After 30 minutes of incubation in the dark, the reaction is stopped by adding 50 μl of 14% sulfuric acid to each well. The reaction results are taken into account using a spectrophotomegre with a vertical beam by measuring light absorption at 492 nm. The functional activity of the drug factor B is calculated according to a standard curve. This method was used to determine the activity of factor B in samples with a known content of factor B. The results are shown in the table.

Example 2. Determination of the functional activity of the preparation of factor B is carried out analogously to example 1, but immunoglobulin G is used as an alternative pathway activator. The results are shown in the table.

Example 3. Determination of the functional activity of the preparation of factor B is carried out analogously to example 1, but as an activator of the alternative pathway, the preparation of component C3 of guinea pig is used. The results are shown in the table.

Example 4. Determination of the functional activity of the preparation of factor B is carried out analogously to example 1, but as an activator of the alternative pathway, use a lipopolysaccharide (LPS - preparation of the bacterial cell wall, pyrogenal). The results are shown in the table.

Literature

1. Kozlov L.V., Solyakov L.S. The possibility of the participation of the zymogenic forms of factors B and D in the activation of the alternative pathway of the complement system. / Bioorganic Chemistry, 1982, v. 8, No. 3, p. 342-348.

Claims (1)

A method for determining the functional activity of a factor In a human complement, characterized in that an alternative pathway activator selected from the series immunoglobulin A, immunoglobulin G, component C3, lipopolysaccharide is sorbed in the wells of the microplate, then a solution containing RB reagent is added to the wells of the microplate, and the analyzed sample containing human complement factor B with an unknown activity is incubated in the presence of Mg ²⁺ ions and in the absence of Ca ²⁺ ions, poured contents of the wells, and then making a conjugate fe ment with antibodies against human C3 component and a substrate of the enzyme, followed by calculation factor activity The amount of product formed by enzymatic reaction.